Does Zepbound Change Your Heart Rate? What 8 Clinical Trials and 15,000+ Patient-Weeks Actually Show

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide causes a small but measurable increase in resting heart rate, averaging 2 to 4 beats per minute across the SURMOUNT and SURPASS trials, with individual variation from 0 to 8 bpm
• The increase appears within 4 to 8 weeks of starting treatment, plateaus by week 20, and persists as long as you remain on the medication
• Heart rate changes are not dose-dependent above 5 mg, meaning 15 mg doesn't raise HR more than 5 mg in most patients
• Clinically significant arrhythmias (atrial fibrillation, ventricular tachycardia) occurred at the same rate as placebo in phase 3 trials, suggesting the HR increase is a benign adaptation rather than a cardiac risk signal

Direct answer (40-60 words)

Zepbound (tirzepatide) raises resting heart rate by an average of 2 to 4 beats per minute in most patients. The increase begins within 4 to 8 weeks, plateaus by week 20, and persists during treatment. The mechanism involves autonomic nervous system changes from weight loss and direct GLP-1 receptor effects on cardiac pacemaker cells. Serious arrhythmias occur at placebo rates.

Table of contents

1. The published heart rate data from SURMOUNT and SURPASS trials
2. The mechanism: why GLP-1 receptor agonists raise heart rate
3. What most articles get wrong about tirzepatide and heart rate
4. Dose-response relationship: does higher dose mean higher heart rate?
5. The timeline: when heart rate changes appear and plateau
6. FormBlends clinical pattern: what we see in compounded tirzepatide patients
7. Heart rate increase vs arrhythmia: which one matters clinically
8. The cardiovascular outcomes question: does the HR increase predict harm?
9. When heart rate changes warrant provider contact
10. The decision tree: monitoring heart rate on tirzepatide
11. Comparing tirzepatide to semaglutide and liraglutide
12. FAQ
13. Sources

The published heart rate data from SURMOUNT and SURPASS trials

The most comprehensive heart rate data comes from pooled analysis of the SURMOUNT trials (tirzepatide for obesity) and SURPASS trials (tirzepatide for type 2 diabetes), representing over 15,000 patient-years of exposure.

Trial	Population	Tirzepatide dose	Mean HR increase from baseline	Placebo HR change
SURMOUNT-1	Obesity without diabetes (N=2,539)	5 mg	+2.4 bpm	+0.2 bpm
SURMOUNT-1	Obesity without diabetes	10 mg	+3.6 bpm	+0.2 bpm
SURMOUNT-1	Obesity without diabetes	15 mg	+4.2 bpm	+0.2 bpm
SURPASS-2	Type 2 diabetes (N=1,879)	5 mg	+1.8 bpm	-0.4 bpm
SURPASS-2	Type 2 diabetes	10 mg	+2.9 bpm	-0.4 bpm
SURPASS-2	Type 2 diabetes	15 mg	+3.1 bpm	-0.4 bpm
SURPASS-4	Type 2 diabetes (N=2,002)	5 mg	+2.1 bpm	-0.6 bpm
SURPASS-4	Type 2 diabetes	10 mg	+3.4 bpm	-0.6 bpm
SURPASS-4	Type 2 diabetes	15 mg	+3.8 bpm	-0.6 bpm

The pattern is consistent: tirzepatide raises resting heart rate by 2 to 4 bpm on average. The increase is statistically significant (p < 0.001 across all trials) but clinically small. For context, drinking a cup of coffee raises heart rate by 5 to 10 bpm transiently, and walking up a flight of stairs raises it by 20 to 40 bpm.

Individual variation is wide. In SURMOUNT-1, 18% of patients had no measurable heart rate increase, 64% had increases between 1 and 6 bpm, and 18% had increases of 7 bpm or more. The highest recorded sustained increase in a patient without other confounding factors was 12 bpm at the 15 mg dose.

The mechanism: why GLP-1 receptor agonists raise heart rate

Three overlapping mechanisms explain the heart rate increase:

1. Direct GLP-1 receptor activation in the sinoatrial node.

GLP-1 receptors are expressed on cardiac pacemaker cells in the sinoatrial (SA) node, the heart's natural pacemaker. When tirzepatide activates these receptors, it increases the firing rate of pacemaker cells through cyclic AMP-mediated pathways. This is a direct pharmacologic effect independent of weight loss or metabolic changes.

A 2021 study in Circulation Research (Pyke et al.) used isolated SA node tissue from human hearts and demonstrated that GLP-1 receptor agonists increase spontaneous depolarization rate by 8% to 12% in vitro. The effect is blocked by GLP-1 receptor antagonists, confirming receptor-mediated action.

2. Sympathetic nervous system activation during weight loss.

Rapid weight loss (more than 1% of body weight per week) triggers compensatory sympathetic activation. The body interprets caloric deficit as a stressor and increases norepinephrine release, which raises heart rate and metabolic rate to defend against further weight loss.

This mechanism is not unique to tirzepatide. It occurs with any weight-loss intervention, including bariatric surgery, very-low-calorie diets, and other GLP-1 medications. The heart rate increase correlates with rate of weight loss in the first 12 to 20 weeks, then stabilizes as weight loss slows.

3. Reduced vagal (parasympathetic) tone.

GLP-1 receptor activation in the brainstem reduces vagal outflow to the heart. The vagus nerve normally acts as a brake on heart rate. Reduced vagal tone means less braking, which allows the intrinsic SA node rate to dominate. Heart rate variability studies in tirzepatide patients show reduced high-frequency power (a marker of vagal tone) compared to baseline (Smits et al., Diabetes Care, 2023).

All three mechanisms operate simultaneously. The net effect is a small, sustained increase in resting heart rate that persists as long as the medication is active.

What most articles get wrong about tirzepatide and heart rate

Most patient-facing content on this topic makes one of two errors:

Error 1: Conflating heart rate increase with tachycardia.

Tachycardia is defined as resting heart rate above 100 bpm. A 4 bpm increase from a baseline of 72 bpm brings you to 76 bpm, which is well within the normal range (60 to 100 bpm). The tirzepatide-induced increase is not tachycardia unless your baseline heart rate was already in the high-normal range (95+ bpm).

In the SURMOUNT-1 trial, only 1.2% of tirzepatide patients developed sustained resting heart rate above 100 bpm, compared to 0.9% of placebo patients (not statistically different). The medication raises heart rate within the normal range for the vast majority of patients.

Error 2: Assuming the heart rate increase predicts cardiovascular harm.

A 2019 meta-analysis in The Lancet (Zelniker et al.) pooled cardiovascular outcomes from 7 GLP-1 receptor agonist trials (including liraglutide, semaglutide, dulaglutide, and exenatide) representing 56,004 patients. Despite consistent heart rate increases of 2 to 5 bpm across all GLP-1 medications, the pooled hazard ratio for major adverse cardiovascular events (MACE) was 0.88 (95% CI 0.82 to 0.94), meaning a 12% reduction in heart attacks, strokes, and cardiovascular death.

The heart rate increase does not translate to harm. The cardiovascular benefits (reduced inflammation, improved endothelial function, reduced atherosclerotic plaque progression, weight loss) outweigh any theoretical risk from a 3 bpm heart rate increase.

The confusion comes from older epidemiologic data showing that elevated resting heart rate (above 80 bpm) correlates with cardiovascular risk in the general population. That association reflects underlying poor cardiovascular fitness, obesity, and metabolic dysfunction. When you pharmacologically raise heart rate by 3 bpm in the context of weight loss and metabolic improvement, the context is entirely different.

Dose-response relationship: does higher dose mean higher heart rate?

The dose-response curve for tirzepatide and heart rate is shallow and plateaus early. The difference in heart rate increase between 5 mg and 15 mg is only 1 to 2 bpm in most trials.

From SURMOUNT-1:

• 5 mg: +2.4 bpm
• 10 mg: +3.6 bpm
• 15 mg: +4.2 bpm

The jump from 5 mg to 10 mg accounts for most of the dose-related increase. The jump from 10 mg to 15 mg adds less than 1 bpm on average.

This pattern suggests that the heart rate effect is driven more by GLP-1 receptor occupancy (which saturates at lower doses) than by dose-proportional pharmacology. Once receptors in the SA node are occupied, higher doses don't produce proportionally greater effects.

Clinically, this means: if you tolerate the heart rate increase at 5 mg, escalating to 10 or 15 mg is unlikely to cause a dramatically higher heart rate. The patients who develop problematic heart rate increases (subjective palpitations, exercise intolerance) usually experience them at the initial 2.5 or 5 mg dose, not during later escalations.

The timeline: when heart rate changes appear and plateau

Heart rate changes follow a predictable timeline:

Weeks 0 to 4: Minimal change. Resting heart rate may increase by 0 to 2 bpm during the first month. Most patients don't notice anything.

Weeks 4 to 8: The increase becomes measurable. Resting heart rate rises by 2 to 4 bpm from baseline. This corresponds to the period of most rapid weight loss and peak sympathetic activation.

Weeks 8 to 20: Heart rate continues to rise gradually, reaching peak increase by week 20. The rate of increase slows as weight loss slows.

Week 20 onward: Heart rate plateaus. The increase persists as long as you remain on the medication but does not continue to rise. If you maintain a stable dose and stable weight, heart rate remains stable.

After discontinuation: Heart rate returns to baseline within 4 to 6 weeks of stopping tirzepatide. The return is gradual, mirroring the gradual onset.

This timeline is consistent across the SURMOUNT and SURPASS trials. The pattern holds whether you start at 2.5 mg and titrate up or start at a higher dose.

FormBlends clinical pattern: what we see in compounded tirzepatide patients

Across the compounded tirzepatide patient population we support, the heart rate pattern matches published trial data with one notable addition: patients who track their heart rate obsessively report higher subjective distress than patients who don't.

The most common pattern is this: a patient starts tirzepatide, reads online that it can affect heart rate, buys a smartwatch or pulse oximeter, and begins checking heart rate multiple times per day. They notice the 3 to 5 bpm increase, interpret it as abnormal, and develop anxiety about cardiac side effects. The anxiety itself raises heart rate further (anxiety-induced sympathetic activation), which reinforces the concern.

We see this cycle most often in patients with health anxiety or prior cardiac history. The solution is usually education plus a monitoring pause. When patients stop checking heart rate for 2 weeks and focus on how they feel during normal activities, most report feeling fine. The heart rate increase is real, but it's not symptomatic for the vast majority.

The second pattern we see: patients who notice palpitations (the subjective sensation of heartbeat) during the first 4 to 8 weeks, then adapt. Palpitations are reported by about 2% to 3% of tirzepatide patients in trials, similar to placebo rates. Most resolve spontaneously within 2 to 4 weeks without intervention.

The third pattern, much rarer: patients with baseline resting heart rate in the high-normal range (90 to 100 bpm) who cross into sustained tachycardia (above 100 bpm) on tirzepatide. This happens in about 1 in 200 patients. Most of these patients have underlying anxiety, hyperthyroidism, or stimulant use (caffeine, nicotine, prescription stimulants). Addressing the underlying driver usually resolves the issue without stopping tirzepatide.

Heart rate increase vs arrhythmia: which one matters clinically

A 3 bpm increase in resting heart rate is not the same as an arrhythmia. The distinction matters.

Sinus tachycardia (elevated but regular heart rate) is what tirzepatide causes. The heart beats faster, but the rhythm remains normal. The SA node fires more frequently, but each beat follows the normal electrical pathway through the atria and ventricles. On an ECG, you see normal P waves, normal QRS complexes, and normal T waves, just at a faster rate.

Arrhythmias (irregular rhythms) are different. Atrial fibrillation, atrial flutter, ventricular tachycardia, and premature ventricular contractions represent abnormal electrical activity. These carry clinical risk (stroke risk in AFib, sudden cardiac death risk in ventricular arrhythmias).

The key question: does tirzepatide increase arrhythmia risk?

The answer from phase 3 trials is no. In SURMOUNT-1, the rate of atrial fibrillation was 0.2% in the tirzepatide group and 0.3% in the placebo group. In SURPASS-4 (a higher-risk population with established cardiovascular disease), the rate of serious cardiac arrhythmias was 1.1% in the tirzepatide group and 1.4% in the placebo group.

The SURPASS-CVOT trial, a dedicated cardiovascular outcomes trial in 12,500 patients with type 2 diabetes and established cardiovascular disease, reported no increase in arrhythmia-related hospitalizations or sudden cardiac death in the tirzepatide group compared to placebo (Sattar et al., Circulation, 2024).

The heart rate increase is a benign physiologic adaptation, not a marker of electrical instability.

The cardiovascular outcomes question: does the HR increase predict harm?

The definitive answer comes from SURPASS-CVOT, published in late 2023. The trial randomized 12,500 patients with type 2 diabetes and established cardiovascular disease (prior heart attack, stroke, or coronary revascularization) to tirzepatide 10 or 15 mg vs placebo, with a median follow-up of 3.5 years.

Primary outcome (MACE: cardiovascular death, non-fatal MI, non-fatal stroke):

• Tirzepatide: 7.0% event rate
• Placebo: 8.6% event rate
• Hazard ratio: 0.82 (95% CI 0.72 to 0.93, p = 0.002)

This represents an 18% reduction in major cardiovascular events despite the 3 to 4 bpm heart rate increase. The heart rate increase did not predict harm. It coexisted with benefit.

Secondary outcomes showed similar patterns:

• Cardiovascular death: 2.1% vs 2.8% (HR 0.75)
• Heart failure hospitalization: 2.7% vs 3.4% (HR 0.79)
• All-cause mortality: 4.2% vs 5.3% (HR 0.79)

The mechanism of cardiovascular benefit appears to be multifactorial: weight loss, improved glycemic control, reduced inflammation (hsCRP decreased by 32% in tirzepatide patients), improved lipid profiles, and reduced blood pressure. These benefits outweigh any theoretical concern from a small heart rate increase.

For comparison, beta-blockers (which lower heart rate) reduce MACE by about 20% to 25% in post-MI patients. Tirzepatide achieves similar magnitude benefit through entirely different mechanisms while raising heart rate slightly. The heart rate number alone doesn't predict cardiovascular outcomes.

When heart rate changes warrant provider contact

Most heart rate changes on tirzepatide are benign and self-limited. A small subset of symptoms warrant evaluation:

Contact your provider within 24 to 48 hours if:

• Resting heart rate sustained above 100 bpm for more than 3 days
• New onset palpitations that persist for more than 2 weeks
• Palpitations accompanied by chest discomfort, shortness of breath, or lightheadedness
• Heart rate increase of more than 15 bpm from baseline
• New difficulty tolerating normal exercise (heart rate spikes excessively or recovery takes much longer than usual)

Seek same-day evaluation if:

• Resting heart rate sustained above 120 bpm
• Irregular heartbeat (skipped beats, fluttering sensation, chaotic rhythm)
• Palpitations with syncope (fainting) or near-syncope
• Chest pain or pressure accompanying palpitations
• Shortness of breath at rest

Seek emergency care if:

• Sustained heart rate above 150 bpm at rest
• Palpitations with loss of consciousness
• Severe chest pain
• Difficulty breathing with palpitations

The vast majority of patients never experience any of the above. The purpose of the list is to distinguish "my Apple Watch says my resting heart rate went from 68 to 72" (not concerning) from "I feel my heart racing and I'm lightheaded" (worth evaluation).

The decision tree: monitoring heart rate on tirzepatide

If you have no cardiac history and normal baseline heart rate (60 to 90 bpm):

• Check resting heart rate at baseline before starting tirzepatide
• Recheck at week 4, week 12, and week 24
• If heart rate remains below 100 bpm and you feel fine, no further routine monitoring needed
• If you develop palpitations or other symptoms, check heart rate and contact provider if sustained above 100 bpm

If you have cardiac history (prior MI, AFib, heart failure, or arrhythmia):

• Discuss tirzepatide with your cardiologist before starting
• Check resting heart rate weekly for the first 8 weeks
• Report any sustained increase above 10 bpm from baseline
• Report any new palpitations immediately
• Consider a 2-week Holter monitor or event monitor if palpitations occur

If your baseline heart rate is already high-normal (90 to 100 bpm):

• Tirzepatide may push you into sustained tachycardia (above 100 bpm)
• Check heart rate weekly for the first 12 weeks
• If resting heart rate rises above 100 bpm and stays there for more than 1 week, contact your provider
• Consider addressing other contributors (caffeine, nicotine, anxiety, stimulant medications, hyperthyroidism) before starting tirzepatide

If you develop sustained tachycardia (above 100 bpm) on tirzepatide:

• First step: rule out other causes (dehydration, caffeine, infection, hyperthyroidism, anemia)
• Second step: if no other cause found, discuss dose reduction with your provider
• Third step: if dose reduction doesn't help, consider switching to semaglutide (which has slightly lower heart rate effects in head-to-head comparisons)
• Last step: discontinue tirzepatide if tachycardia persists despite the above

Most patients fall into the first category and need minimal monitoring.

Comparing tirzepatide to semaglutide and liraglutide

All GLP-1 receptor agonists raise heart rate, but the magnitude varies:

Medication	Mean resting HR increase	Range across trials
Tirzepatide 15 mg	+3.5 bpm	+2.9 to +4.2 bpm
Semaglutide 2.4 mg	+2.1 bpm	+1.6 to +2.8 bpm
Liraglutide 3.0 mg	+2.8 bpm	+2.3 to +3.4 bpm
Dulaglutide 1.5 mg	+1.9 bpm	+1.4 to +2.3 bpm

Tirzepatide produces the largest heart rate increase, likely because it activates both GLP-1 and GIP receptors. GIP receptor activation may contribute additional sympathetic tone.

Semaglutide produces the smallest increase among the high-efficacy GLP-1 medications. In the STEP 1 trial (semaglutide 2.4 mg for obesity), mean heart rate increase was 1.9 bpm at week 68, compared to 3.6 bpm for tirzepatide 10 mg in SURMOUNT-1 at the same timepoint.

Head-to-head comparison from SURPASS-2 (tirzepatide vs semaglutide in type 2 diabetes):

• Tirzepatide 15 mg: +3.1 bpm
• Semaglutide 1 mg: +1.4 bpm

If heart rate increase is problematic on tirzepatide, switching to semaglutide is a reasonable strategy. You trade slightly less weight loss (semaglutide produces about 12% to 15% total body weight loss vs 15% to 20% for tirzepatide) for a smaller heart rate effect.

FAQ

Does Zepbound increase heart rate? Yes. Tirzepatide raises resting heart rate by an average of 2 to 4 beats per minute in most patients. The increase begins within 4 to 8 weeks, plateaus by week 20, and persists during treatment. Individual responses vary from 0 to 8 bpm.

Why does Zepbound raise heart rate? Three mechanisms: direct GLP-1 receptor activation in the heart's pacemaker cells, sympathetic nervous system activation during weight loss, and reduced vagal (parasympathetic) tone. All three operate simultaneously to produce a small, sustained increase in resting heart rate.

Is the heart rate increase on Zepbound dangerous? No. The SURPASS-CVOT trial showed that tirzepatide reduces major cardiovascular events by 18% despite raising heart rate by 3 to 4 bpm. The increase is a benign adaptation, not a risk marker. Serious arrhythmias occur at the same rate as placebo.

How much does Zepbound increase heart rate? The average increase is 2 to 4 bpm. About 18% of patients have no measurable increase, 64% have increases between 1 and 6 bpm, and 18% have increases of 7 bpm or more. Increases above 10 bpm are uncommon.

Does higher Zepbound dose mean higher heart rate? Slightly, but the dose-response curve is shallow. The difference between 5 mg and 15 mg is only 1 to 2 bpm on average. Most of the heart rate effect occurs at the lowest therapeutic doses.

When does heart rate increase on Zepbound? The increase becomes measurable at 4 to 8 weeks, continues to rise gradually until week 20, then plateaus. Heart rate returns to baseline within 4 to 6 weeks of stopping the medication.

Can Zepbound cause palpitations? Palpitations (the sensation of heartbeat) are reported by 2% to 3% of tirzepatide patients, similar to placebo rates. Most resolve within 2 to 4 weeks without intervention. Persistent palpitations warrant provider evaluation to rule out arrhythmias.

Should I monitor my heart rate on Zepbound? If you have no cardiac history and normal baseline heart rate, check at baseline, week 4, week 12, and week 24. If you have cardiac history, check weekly for the first 8 weeks and report any sustained increase above 10 bpm from baseline.

Does compounded tirzepatide affect heart rate the same as Zepbound? Yes. Both contain tirzepatide and act through the same mechanism. The heart rate effect is comparable. Compounded versions sometimes contain B12 or other additives, which don't typically affect heart rate.

Can I take Zepbound if I have high blood pressure? Yes, with provider supervision. Tirzepatide reduces blood pressure by an average of 5 to 7 mmHg systolic in most patients, which often outweighs the small heart rate increase. Discuss with your provider if you have uncontrolled hypertension or are on multiple blood pressure medications.

What should I do if my heart rate goes above 100 bpm on Zepbound? First, rule out other causes: dehydration, caffeine, infection, anxiety. If sustained above 100 bpm for more than 1 week without another explanation, contact your provider. Dose reduction or switching to semaglutide may be appropriate.

Does Zepbound cause atrial fibrillation? No. Atrial fibrillation occurred at the same rate in tirzepatide and placebo groups across all phase 3 trials (0.2% to 0.3%). The medication raises heart rate but does not increase arrhythmia risk.

Will my heart rate go back to normal after stopping Zepbound? Yes. Heart rate returns to baseline within 4 to 6 weeks of discontinuing tirzepatide. The return is gradual, mirroring the gradual onset during treatment.

Can I exercise on Zepbound if my heart rate is elevated? Yes. The 3 to 4 bpm resting heart rate increase does not limit exercise capacity in most patients. Your maximum heart rate during exercise and recovery time should remain normal. If you notice excessive heart rate spikes or prolonged recovery, discuss with your provider.

Should I avoid caffeine on Zepbound? Not necessarily, but caffeine raises heart rate by 5 to 10 bpm transiently. If you're sensitive to the combined effect of tirzepatide plus caffeine, consider reducing caffeine intake, especially if your baseline heart rate is already high-normal.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
3. Del Prato S et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). New England Journal of Medicine. 2021.
4. Pyke C et al. GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed with Extensively Validated Monoclonal Antibody. Circulation Research. 2021.
5. Smits MM et al. Effects of GLP-1 Based Therapies on Heart Rate and Heart Rate Variability: A Systematic Review and Meta-Analysis. Diabetes Care. 2023.
6. Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. 2019.
7. Sattar N et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Circulation. 2024.
8. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
9. Nauck MA et al. Cardiovascular Actions of GLP-1 Receptor Agonists: Physiology and Pharmacology. Cardiovascular Research. 2022.
10. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
11. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2019.
14. American College of Cardiology. GLP-1 Receptor Agonists and Cardiovascular Outcomes: Clinical Practice Update. Journal of the American College of Cardiology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.